Julian Kricheldorff1, Eva Maria Fallenberg, Christine Solbach, Claudia Gerber-Schäfer, Christoph Rancsó, Uwe von Fritschen. 1. Department of Plastic and Esthetic Surgery, Hand Surgery, Helios Hospital Emil von Behring, Berlin; Department of Radiology, Mammography Section, Charité University Medicine Berlin, Virchow Hospital Campus; Breast Center, Department of Gynecology and Obstetrics, University Hospital Frankfurt; Vivantes Breast Center, Am Urban Hospital, Berlin; Institute for Tissue Diagnostics Berlin Medical Center, Helios Hospital Emil von Behring, Berlin; Department of Plastic and Esthetic Surgery, Hand Surgery, Helios Hospital Emil von Behring, Berlin.
Abstract
BACKGROUND: There has been increasing evidence in recent years that breast implants can, in rare cases, be associated with the development of an anaplastic large-cell lymphoma (ALCL). METHODS: This review is based on relevant publications retrieved by a selective search in PubMed for articles that appeared from the time of the initial description of breast-implant-associated ALCL onward (1997 to January 2018), and by a further search in German nationwide databases. RESULTS: 516 pathologically confirmed cases of breast-implant-associated (BIA) ALCL were documented around the world until February 2018; seven of these arose in Germany and were reported to the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). In approximately 80% of the affected women, the BIA-ALCL manifested itself as a late-developing seroma at the implant site; in the rest, as a solid tumor with or without an accompanying seroma. The mean implant exposure time ranged from 7 to 13 years on average. 16 fatalities have been reported worldwide. Among the 7 cases reported in Germany, four women had undergone breast reconstruction with implants after breast cancer surgery, and two had undergone breast augmentation surgery. In all patients, the entire capsule-and-implant unit was resected. One patient underwent chemotherapy and one further patient underwent chemotherapy and adjuvant radiotherapy. CONCLUSION: The risk that a woman with breast implants will develop a primary anaplastic large-cell lymphoma is estimated at 0.35 to 1 case per million persons per year. The incidence of implant-associated ALCL is thus very low, yet nevertheless markedly higher than that of other primary lymphomas of the breast. Because of the low case numbers, recommendations for the diagnostic evaluation and treatment of this entity have not been adequately evaluated. Treatment with primary curative intent for BIA-ALCL confers a much better prognosis than when performed for a systemic ALCL. Whenever a patient with a breast implant presents with a late-developing seroma, BIA-ALCL should be included in the differential diagnosis. This diagnosis is reportable.
BACKGROUND: There has been increasing evidence in recent years that breast implants can, in rare cases, be associated with the development of an anaplastic large-cell lymphoma (ALCL). METHODS: This review is based on relevant publications retrieved by a selective search in PubMed for articles that appeared from the time of the initial description of breast-implant-associated ALCL onward (1997 to January 2018), and by a further search in German nationwide databases. RESULTS: 516 pathologically confirmed cases of breast-implant-associated (BIA) ALCL were documented around the world until February 2018; seven of these arose in Germany and were reported to the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). In approximately 80% of the affected women, the BIA-ALCL manifested itself as a late-developing seroma at the implant site; in the rest, as a solid tumor with or without an accompanying seroma. The mean implant exposure time ranged from 7 to 13 years on average. 16 fatalities have been reported worldwide. Among the 7 cases reported in Germany, four women had undergone breast reconstruction with implants after breast cancer surgery, and two had undergone breast augmentation surgery. In all patients, the entire capsule-and-implant unit was resected. One patient underwent chemotherapy and one further patient underwent chemotherapy and adjuvant radiotherapy. CONCLUSION: The risk that a woman with breast implants will develop a primary anaplastic large-cell lymphoma is estimated at 0.35 to 1 case per million persons per year. The incidence of implant-associated ALCL is thus very low, yet nevertheless markedly higher than that of other primary lymphomas of the breast. Because of the low case numbers, recommendations for the diagnostic evaluation and treatment of this entity have not been adequately evaluated. Treatment with primary curative intent for BIA-ALCL confers a much better prognosis than when performed for a systemic ALCL. Whenever a patient with a breast implant presents with a late-developing seroma, BIA-ALCL should be included in the differential diagnosis. This diagnosis is reportable.
Authors: Erin L Doren; Roberto N Miranda; Jesse C Selber; Patrick B Garvey; Jun Liu; L Jeffrey Medeiros; Charles E Butler; Mark W Clemens Journal: Plast Reconstr Surg Date: 2017-05 Impact factor: 4.730
Authors: Dhivya R Srinivasa; Roberto N Miranda; Arminder Kaura; Ashleigh M Francis; Antonella Campanale; Rosaria Boldrini; Janette Alexander; Anand K Deva; Paula R Gravina; L Jeffrey Medeiros; Karen Nast; Charles E Butler; Mark W Clemens Journal: Plast Reconstr Surg Date: 2017-05 Impact factor: 4.730
Authors: Tariq N Aladily; L Jeffrey Medeiros; Mitual B Amin; Nisreen Haideri; Dongjiu Ye; Sergio J Azevedo; Jeffrey L Jorgensen; Mariza de Peralta-Venturina; Eid B Mustafa; Ken H Young; M James You; Luis E Fayad; Ann Marie Blenc; Roberto N Miranda Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Garry S Brody; Dennis Deapen; Clive R Taylor; Lauren Pinter-Brown; Sarah Rose House-Lightner; James S Andersen; Grant Carlson; Melissa G Lechner; Alan L Epstein Journal: Plast Reconstr Surg Date: 2015-03 Impact factor: 4.730
Authors: M Orciani; G Sorgentoni; M Torresetti; Roberto Di Primio; G Di Benedetto Journal: Breast Cancer Res Treat Date: 2016-03-08 Impact factor: 4.872
Authors: Kirill A Lyapichev; Sergio Piña-Oviedo; L Jeffrey Medeiros; Mark G Evans; Hui Liu; Alonso R Miranda; Kelly K Hunt; Mark W Clemens; John M Stewart; Mitual B Amin; Andres E Quesada; Siaw Ming Chai; Arianna Di Napoli; Arthy Yoga; Sanat K Dave; Ignacio I Wistuba; Yun Wu; Carlos E Bueso-Ramos; Ellen J Schlette; Maria C Ferrufino-Schmidt; Sanam Loghavi; Joseph D Khoury; Ken H Young; Roberto N Miranda Journal: Mod Pathol Date: 2019-08-05 Impact factor: 7.842